Compare Stocks → Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNYSE:AMT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.04-6.4%$9.66$2.09▼$14.84$499.07M0.055.56 million shs3.63 million shsAMTAmerican Tower$172.02-0.1%$193.26$154.58▼$219.10$80.22B0.672.42 million shs2.73 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-0.40%-10.48%-23.73%-32.68%+37.98%AMTAmerican Tower-3.33%-10.75%-12.74%-15.98%-17.55%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.1823 of 5 stars3.32.00.00.01.91.70.0AMTAmerican Tower4.9191 of 5 stars4.43.02.53.12.72.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.67Moderate Buy$15.00113.07% UpsideAMTAmerican Tower2.82Moderate Buy$217.3626.36% UpsideCurrent Analyst RatingsLatest AMT, 4DX, ADR, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024AMTAmerican TowerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$183.00 ➝ $196.004/8/2024AMTAmerican TowerMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$205.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/5/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$224.00 ➝ $234.002/28/2024AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$235.00 ➝ $228.002/28/2024AMTAmerican TowerJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$236.00 ➝ $230.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.001/24/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$229.00 ➝ $224.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,160.62N/AN/A$2.75 per share2.56AMTAmerican Tower$11.14B7.20$9.57 per share17.98$23.30 per share7.38Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)AMTAmerican Tower$1.48B$3.1854.0916.351.2413.31%12.80%2.24%4/30/2024 (Confirmed)Latest AMT, 4DX, ADR, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2024N/AAMTAmerican Tower$2.45N/A-$2.45N/AN/AN/A 2/27/202412/31/2023AMTAmerican Tower$2.10$0.94-$1.16$0.18$2.74 billion$2.79 billion DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.483.77%+21.62%203.77%N/ALatest AMT, 4DX, ADR, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/14/2024AMTAmerican Towerquarterly$1.623.3%4/11/20244/12/20244/26/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A17.2617.26AMTAmerican Tower3.290.690.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5270.89 million67.99 millionOptionableAMTAmerican Tower5,643466.35 million465.23 millionOptionableAMT, 4DX, ADR, and ALT HeadlinesSourceHeadlineDaiwa Securities Group Inc. Trims Stake in American Tower Co. (NYSE:AMT)marketbeat.com - April 17 at 6:35 PMInvest Like a Hawk: 7 Stocks to Own If the Fed Stays Toughinvestorplace.com - April 17 at 12:55 PMSVB Wealth LLC Lowers Stock Holdings in American Tower Co. (NYSE:AMT)marketbeat.com - April 16 at 11:28 AMMorgan Stanley Sticks to Its Hold Rating for American Tower (AMT)markets.businessinsider.com - April 16 at 9:13 AMAmerican Tower (NYSE:AMT) Given New $196.00 Price Target at Morgan Stanleyamericanbankingnews.com - April 16 at 4:50 AMAmerican Tower Co. (NYSE:AMT) Shares Purchased by First American Trust FSBmarketbeat.com - April 15 at 9:50 PMAmerican Tower (NYSE:AMT) PT Raised to $196.00marketbeat.com - April 15 at 12:16 PMLouisiana State Employees Retirement System Makes New Investment in American Tower Co. (NYSE:AMT)marketbeat.com - April 14 at 10:55 AMAmerican Tower (NYSE:AMT): An Attractive REIT Stock Backed by Analystsmsn.com - April 12 at 2:21 PMImpax Asset Management Group plc Buys Shares of 18,093 American Tower Co. (NYSE:AMT)marketbeat.com - April 11 at 8:00 AMAmerican Tower Sees Unusually High Options Volume (NYSE:AMT)americanbankingnews.com - April 11 at 2:34 AMInvestors Buy Large Volume of Call Options on American Tower (NYSE:AMT)marketbeat.com - April 10 at 8:16 PMReal-Estate Stocks Slump After Inflation Printfinance.yahoo.com - April 10 at 3:45 PMAmerican Tower Co. (NYSE:AMT) Shares Sold by Value Partners Investments Inc.marketbeat.com - April 10 at 12:47 PMSoltis Investment Advisors LLC Acquires 7,414 Shares of American Tower Co. (NYSE:AMT)marketbeat.com - April 9 at 7:37 PMTech-Driven Education: American Tower & ProFuturo Collaboza.investing.com - April 9 at 1:30 PMHere's Why You Should Keep American Tower (AMT) in Your Kittyzacks.com - April 9 at 11:11 AMCoreSite Helps Customers Accelerate Artificial Intelligence Adoption as NVIDIA DGX-Ready Data Center Partnerbusinesswire.com - April 9 at 11:00 AMMizuho Initiates Coverage on American Tower (NYSE:AMT)americanbankingnews.com - April 9 at 3:46 AMXLRE: Quality Beats Quantity Once Againseekingalpha.com - April 9 at 1:42 AMIHS Holding Limited: Economic Crisis Brings Opportunityseekingalpha.com - April 8 at 3:41 PMAssessing American Tower: Insights From 5 Financial Analystsmarkets.businessinsider.com - April 8 at 8:42 AMAmerican Tower (NYSE:AMT) Receives New Coverage from Analysts at Mizuhomarketbeat.com - April 8 at 7:24 AMBuy Rating for American Tower: Strategic Shifts and Strong Outlook Justify Positive Stancemarkets.businessinsider.com - April 8 at 1:42 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? All Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American TowerNYSE:AMTAmerican Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.